Detalhe da pesquisa
1.
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study.
Lancet Oncol
; 24(2): 187-194, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36640790
2.
Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study.
Eur J Nucl Med Mol Imaging
; 50(8): 2486-2500, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36877234
3.
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Neuroendocrinology
; 112(1): 88-100, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-33508849
4.
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(8): 1126-1138, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34237250
5.
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
Oncologist
; 26(11): 941-949, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34190375
6.
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
Oncologist
; 26(4): 294-301, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33301235
7.
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.
Pancreatology
; 21(1): 215-223, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33358592
8.
Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors.
Oncologist
; 24(12): e1315-e1320, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31332100
9.
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Thyroid
; 34(3): 347-359, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38062732
10.
Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey.
J Neuroendocrinol
; 35(6): e13281, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37290479
11.
Impact of the COVID-19 pandemic in the early-onset colorectal cancer.
Transl Oncol
; 32: 101668, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37031602
12.
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours.
Eur J Cancer
; 188: 39-48, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37196483
13.
DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype.
Cell Rep
; 42(8): 112927, 2023 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37537841
14.
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study.
Endocr Relat Cancer
; 30(6)2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36930250
15.
What is the status of immunotherapy in thyroid neoplasms?
Front Endocrinol (Lausanne)
; 13: 929091, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35992118
16.
Cervical dissecting extravasation of oxaliplatin: A case report.
Mol Clin Oncol
; 16(3): 60, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35127085
17.
The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients.
J Neuroendocrinol
; 34(10): e13196, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36072989
18.
Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy.
World J Gastroenterol
; 28(13): 1304-1314, 2022 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35645544
19.
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
Clin Cancer Res
; 28(8): 1662-1671, 2022 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35042699
20.
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
Clin Transl Oncol
; 24(11): 2155-2165, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35761123